$101.80
0.08%
Nasdaq, Nov 17, 04:00 pm EST. Closed.

Lantheus Holdings Inc Stock price

$101.80
+1.88 1.88% 1M
+8.67 9.31% 6M
+35.25 52.97% YTD
+49.30 93.90% 1Y
+33.60 49.27% 3Y
+72.51 247.56% 5Y
+92.55 1,000.54% 10Y
+95.03 1,403.69% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.08 0.08%

AI Insights on Lantheus Holdings Inc Insights AI Insights on Lantheus Holdings Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Lantheus Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.7b
Enterprise Value
$6.6b
Net debt
positive
Cash
$593.3m
Shares outstanding
65.3m
Valuation
P/E
25.0
P/S | estimate
4.3 | 4.4
EV/Sales | estimate
4.3 | 4.4
EV/FCF | ex SBC
17.1 | 21.4
P/B
5.1
Financial Health
Equity Ratio
48.9%
Return on Equity
21.4%
ROCE
15.5%
ROIC
13.9%
Debt/Equity
0.4
Share-Based Compensation & Dilution
SBC | % of Revenue
$78.1m | 5.0%
SBC as % of FCF
20.1%
SBC Growth 1Y
-9.3%
Share Count Growth 1Y
-4.0%
Shareholder Yield
4.0%
Financials
Revenue | estimate
$1.6b | $1.5b
EBITDA
$409.7m
EBIT
$321.1m
Net Income
$275.3m
Free Cash Flow | ex SBC
$387.8m | $309.7m
Growth
Revenue | estimate
2.4% | -2.1%
EBITDA
-17.9%
EBIT
-26.6%
Net Income
1.6%
Free Cash Flow
-19.0%
Margin
Gross
61.0%
EBITDA
26.3%
EBIT
20.6%
Net
17.7%
Free Cash Flow | ex SBC
24.9% | 19.9%
More
EPS
$4.1
FCF per Share
$5.9
Short interest
6.5%
Employees
1k
Rev per Employee
$1.3m

Lantheus Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Lantheus Holdings Inc forecast:

7x Buy
44%
9x Hold
56%

Analyst Opinions

16 Analysts have issued a Lantheus Holdings Inc forecast:

Buy
44%
Hold
56%

Lantheus Holdings Inc Events

Past Events
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
FEB
26
Q4 2025 Earnings Call
9 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from Lantheus Holdings Inc

Jun '26
+/-
%
1,556 1,556
2% 2%
100%
- Direct Costs 607 607
10% 10%
39%
949 949
2% 2%
61%
- Selling and Administrative Expenses 461 461
17% 17%
30%
- Research and Development Expense 167 167
18% 18%
11%
410 410
18% 18%
26%
- Depreciation and Amortization 89 89
45% 45%
6%
EBIT (Operating Income) EBIT 321 321
27% 27%
21%
Net Profit 275 275
2% 2%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Lantheus Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lantheus Holdings Inc Stock News

Neutral
GlobeNewsWire
●
one day ago
BEDFORD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced results from two pivotal Phase 3 studies evaluating the diagnostic performance of the TAUKLARIFY™ (florquinitau F 18 injection) P...
Neutral
PRNewsWire
●
8 days ago
Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies WALTHAM, Mass., Nov. 9, 2026 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuti...
Neutral
GlobeNewsWire
●
12 days ago
Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A...
More Lantheus Holdings Inc News

Company Profile

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

Head office United States
CEO Brian Markison
Employees 1,193
Founded 1956
Website www.lantheus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today